What is Peptide Receptor Radionuclide Therapy (PRRT)?

**PRRT delivers radiation directly to the tumor to kill cancer cells.**

Some NET cells have proteins on their cell surface called receptors that can bind to hormones such as somatostatin. PRRT with lutetium 177 dotatate (Lu-177) targets these receptors.

**What are the benefits of PRRT?**

PRRT was approved in the US in 2018 to treat adults with pancreatic and gastrointestinal NETs. Patients should test positive for somatostatin receptors to benefit from PRRT. A Gallium 68-Dotatate PET/CT can help to determine the presence of these receptors.

**Studies have shown PRRT can:**

- Increase progression-free survival and likely survival
- Improve the quality of life
- Relieve symptoms
- Decrease tumor size

**What are the side effects of PRRT?**

PRRT is generally well tolerated.

**Common side effects of radiopeptide therapy are:**

- Nausea
- Vomiting
- Abdominal pain
- Fatigue

More serious side effects, such as bone, liver, and kidney toxicity, are less common.